NR3C1 and Cowden syndrome 1: In fact, drug GSEA analyses identified glucocorticoid receptor agonists as the compounds that trigger a signature most significantly opposed to the COVIDCS, providing strong support to the usefulness of our approach as the synthetic glucocorticoid dexamethasone is currently the most widely used treatment for the CS in COVID-19 patients (Fig. 2B,C).